HER2 Support Group Forums - View Single Post - Study offers a differentiated patient-specific solution in minimal residual disease t

News · 01-14-2021, 11:36 PM

Exact Sciences Corp. today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

More...

01-14-2021, 11:36 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,946	Study offers a differentiated patient-specific solution in minimal residual disease t Exact Sciences Corp. today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. More...